An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy. - Querol L; Lewis RA; Hartung HP; Van Doorn PA; Wallstroem E; Luo X; Alonso-Alonso M; Atassi N; Hughes RAC (Journal of the peripheral nervous system : JPNS, 2023)